Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
Frontage (HKG:1521) recorded a net profit of $5.6 million for the nine months ended Sept. 30, up from $200,000 a year prior, a Tuesday Hong Kong bourse filing said.
The biotech firm's revenue rose 0.2% to $191.4 million in the three quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.